Latin America, Middle East & Africa Autoimmune Disease Therapeutics Market (2019-2025)
The Latin America, Middle East and Africa Autoimmune Disease Therapeutics Market would witness market growth of 5.38% CAGR during the forecast period (2019–2025).
Autoimmune diseases are usually chronic and there's no curative treatment for them. Dermatomyositis, Hashimoto's disease of type 1 diabetes, Sjogren's syndrome, Psoriasis are some examples of autoimmune diseases. Systemic treatment of autoimmune diseases and localized treatment of autoimmune disease are two kinds of treatments for autoimmune disease.
The accelerated acceptance of autoimmune disease therapeutics expanded wide accessibility of sophisticated therapy, and an increase in the number of research and development operations are collectively driving the market growth. High original expenses linked to sophisticated therapies, however, restrict the market growth. On the other side, the powerful existence of pipeline drugs and possibilities in emerging economies creates new sector routes.
Based on Indication, the market is segmented into Rheumatic Disease, Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease, and Other Indications. Based on Drug Class, the market is segmented into Anti-Inflammatory, Anti-Hyperglycemics, NSAIDs (Nonsteroidal anti-inflammatory drugs), Interferons and Other Drugs. Based on the Distribution Channel, the market is segmented into Hospital Pharmacy, Online and Retail Pharmacies & Drug Stores. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include ABBOTT Laboratories, Bio-Rad Laboratories, Inc., Johnson and Johnson, GlaxoSmithKline PLC (GSK), Pfizer, Inc., Merck & Co., Inc., Bayer AG, AbbVie, Inc., Amgen, Inc. and Novartis.
Scope of the Study
Market Segmentation:
By Indication
Autoimmune diseases are usually chronic and there's no curative treatment for them. Dermatomyositis, Hashimoto's disease of type 1 diabetes, Sjogren's syndrome, Psoriasis are some examples of autoimmune diseases. Systemic treatment of autoimmune diseases and localized treatment of autoimmune disease are two kinds of treatments for autoimmune disease.
The accelerated acceptance of autoimmune disease therapeutics expanded wide accessibility of sophisticated therapy, and an increase in the number of research and development operations are collectively driving the market growth. High original expenses linked to sophisticated therapies, however, restrict the market growth. On the other side, the powerful existence of pipeline drugs and possibilities in emerging economies creates new sector routes.
Based on Indication, the market is segmented into Rheumatic Disease, Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease, and Other Indications. Based on Drug Class, the market is segmented into Anti-Inflammatory, Anti-Hyperglycemics, NSAIDs (Nonsteroidal anti-inflammatory drugs), Interferons and Other Drugs. Based on the Distribution Channel, the market is segmented into Hospital Pharmacy, Online and Retail Pharmacies & Drug Stores. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include ABBOTT Laboratories, Bio-Rad Laboratories, Inc., Johnson and Johnson, GlaxoSmithKline PLC (GSK), Pfizer, Inc., Merck & Co., Inc., Bayer AG, AbbVie, Inc., Amgen, Inc. and Novartis.
Scope of the Study
Market Segmentation:
By Indication
- Rheumatic Disease
- Diabetes
- Multiple Sclerosis
- Inflammatory Bowel Disease
- Other Indications
- Anti-Inflammatory
- Anti-Hyperglycemics
- NSAIDs
- Interferons
- Other Drugs
- Hospital Pharmacy
- Online
- Retail Pharmacies and Drug Stores
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
- ABBOTT Laboratories
- Bio-Rad Laboratories, Inc.
- Johnson and Johnson
- GlaxoSmithKline PLC (GSK)
- Pfizer, Inc.
- Merck & Co., Inc.
- Bayer AG
- AbbVie, Inc.
- Amgen, Inc.
- Novartis AG
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
CHAPTER 1. MARKET SCOPE & METHODOLOGY
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Autoimmune Disease Therapeutics Market, by Indication
1.4.2 LAMEA Autoimmune Disease Therapeutics Market, by Drug Class
1.4.3 LAMEA Autoimmune Disease Therapeutics Market, by Distribution Channel
1.4.4 LAMEA Autoimmune Disease Therapeutics Market, by Country
1.5 Methodology for the research
CHAPTER 2. MARKET OVERVIEW
2.1 Introduction
2.1.1 Overview
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
CHAPTER 3. LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION
3.1 LAMEA Rheumatic Disease Market by Country
3.2 LAMEA Diabetes Market by Country
3.3 LAMEA Multiple Sclerosis Market by Country
3.4 LAMEA Inflammatory Bowel Disease Market by Country
3.5 LAMEA Other Indications Market by Country
CHAPTER 4. LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS
4.1 LAMEA Anti-Inflammatory Market by Country
4.2 LAMEA Anti-Hyperglycemics Market by Country
4.3 LAMEA NSAIDs Market by Country
4.4 LAMEA Interferons Market by Country
4.5 LAMEA Other Drugs Market by Country
CHAPTER 5. LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL
5.1 LAMEA Hospital Pharmacy Market by Country
5.2 LAMEA Online Market by Country
5.3 LAMEA Retail Pharmacies and Drug Stores Market by Country
CHAPTER 6. LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY COUNTRY
6.1 Brazil Autoimmune Disease Therapeutics Market
6.1.1 Brazil Autoimmune Disease Therapeutics Market by Indication
6.1.2 Brazil Autoimmune Disease Therapeutics Market by Drug Class
6.1.3 Brazil Autoimmune Disease Therapeutics Market by Distribution Channel
6.2 Argentina Autoimmune Disease Therapeutics Market
6.2.1 Argentina Autoimmune Disease Therapeutics Market by Indication
6.2.2 Argentina Autoimmune Disease Therapeutics Market by Drug Class
6.2.3 Argentina Autoimmune Disease Therapeutics Market by Distribution Channel
6.3 UAE Autoimmune Disease Therapeutics Market
6.3.1 UAE Autoimmune Disease Therapeutics Market by Indication
6.3.2 UAE Autoimmune Disease Therapeutics Market by Drug Class
6.3.3 UAE Autoimmune Disease Therapeutics Market by Distribution Channel
6.4 Saudi Arabia Autoimmune Disease Therapeutics Market
6.4.1 Saudi Arabia Autoimmune Disease Therapeutics Market by Indication
6.4.2 Saudi Arabia Autoimmune Disease Therapeutics Market by Drug Class
6.4.3 Saudi Arabia Autoimmune Disease Therapeutics Market by Distribution Channel
6.5 South Africa Autoimmune Disease Therapeutics Market
6.5.1 South Africa Autoimmune Disease Therapeutics Market by Indication
6.5.2 South Africa Autoimmune Disease Therapeutics Market by Drug Class
6.5.3 South Africa Autoimmune Disease Therapeutics Market by Distribution Channel
6.6 Nigeria Autoimmune Disease Therapeutics Market
6.6.1 Nigeria Autoimmune Disease Therapeutics Market by Indication
6.6.2 Nigeria Autoimmune Disease Therapeutics Market by Drug Class
6.6.3 Nigeria Autoimmune Disease Therapeutics Market by Distribution Channel
6.7 Rest of LAMEA Autoimmune Disease Therapeutics Market
6.7.1 Rest of LAMEA Autoimmune Disease Therapeutics Market by Indication
6.7.2 Rest of LAMEA Autoimmune Disease Therapeutics Market by Drug Class
6.7.3 Rest of LAMEA Autoimmune Disease Therapeutics Market by Distribution Channel
CHAPTER 7. COMPANY PROFILES
7.1 ABBOTT Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.2 Bio-Rad Laboratories, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expenses
7.3 Johnson and Johnson
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental &Regional Analysis
7.3.4 Research & Development Expenses
7.3.1 Recent strategies and developments:
7.3.1.1 Collaborations, partnerships and agreements:
7.4 GlaxoSmithKline PLC (GSK)
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Acquisition and mergers:
7.4.5.2 Collaborations, partnerships and agreements:
7.4.5.3 Product launches:
7.5 Pfizer, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Collaborations, partnerships and agreements:
7.5.5.2 Approval:
7.6 Merck & Co., Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expenses
7.6.5 Recent strategies and developments:
7.6.5.1 Collaborations, partnerships and agreements:
7.6.5.2 Acquisition and mergers:
7.7 Bayer AG (Bayer Schering Pharma AG)
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Collaborations, partnerships and agreements:
7.8 AbbVie, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expense
7.8.5 Recent strategies and developments:
7.8.5.1 Collaborations, partnerships and agreements:
7.9 Amgen, Inc.
7.9.1 Company overview
7.9.2 Financial Analysis
7.9.3 Regional Analysis
7.9.4 Research & Development Expense
7.9.5 Recent strategies and developments:
7.9.5.1 Product launches:
7.9.5.2 Collaborations, partnerships and agreements:
7.1 Novartis AG
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Research & Development Expense
7.10.5 Recent strategies and developments:
7.10.5.1 Acquisition and mergers:
7.10.5.2 Collaborations, partnerships and agreements:
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Autoimmune Disease Therapeutics Market, by Indication
1.4.2 LAMEA Autoimmune Disease Therapeutics Market, by Drug Class
1.4.3 LAMEA Autoimmune Disease Therapeutics Market, by Distribution Channel
1.4.4 LAMEA Autoimmune Disease Therapeutics Market, by Country
1.5 Methodology for the research
CHAPTER 2. MARKET OVERVIEW
2.1 Introduction
2.1.1 Overview
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
CHAPTER 3. LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION
3.1 LAMEA Rheumatic Disease Market by Country
3.2 LAMEA Diabetes Market by Country
3.3 LAMEA Multiple Sclerosis Market by Country
3.4 LAMEA Inflammatory Bowel Disease Market by Country
3.5 LAMEA Other Indications Market by Country
CHAPTER 4. LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS
4.1 LAMEA Anti-Inflammatory Market by Country
4.2 LAMEA Anti-Hyperglycemics Market by Country
4.3 LAMEA NSAIDs Market by Country
4.4 LAMEA Interferons Market by Country
4.5 LAMEA Other Drugs Market by Country
CHAPTER 5. LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL
5.1 LAMEA Hospital Pharmacy Market by Country
5.2 LAMEA Online Market by Country
5.3 LAMEA Retail Pharmacies and Drug Stores Market by Country
CHAPTER 6. LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY COUNTRY
6.1 Brazil Autoimmune Disease Therapeutics Market
6.1.1 Brazil Autoimmune Disease Therapeutics Market by Indication
6.1.2 Brazil Autoimmune Disease Therapeutics Market by Drug Class
6.1.3 Brazil Autoimmune Disease Therapeutics Market by Distribution Channel
6.2 Argentina Autoimmune Disease Therapeutics Market
6.2.1 Argentina Autoimmune Disease Therapeutics Market by Indication
6.2.2 Argentina Autoimmune Disease Therapeutics Market by Drug Class
6.2.3 Argentina Autoimmune Disease Therapeutics Market by Distribution Channel
6.3 UAE Autoimmune Disease Therapeutics Market
6.3.1 UAE Autoimmune Disease Therapeutics Market by Indication
6.3.2 UAE Autoimmune Disease Therapeutics Market by Drug Class
6.3.3 UAE Autoimmune Disease Therapeutics Market by Distribution Channel
6.4 Saudi Arabia Autoimmune Disease Therapeutics Market
6.4.1 Saudi Arabia Autoimmune Disease Therapeutics Market by Indication
6.4.2 Saudi Arabia Autoimmune Disease Therapeutics Market by Drug Class
6.4.3 Saudi Arabia Autoimmune Disease Therapeutics Market by Distribution Channel
6.5 South Africa Autoimmune Disease Therapeutics Market
6.5.1 South Africa Autoimmune Disease Therapeutics Market by Indication
6.5.2 South Africa Autoimmune Disease Therapeutics Market by Drug Class
6.5.3 South Africa Autoimmune Disease Therapeutics Market by Distribution Channel
6.6 Nigeria Autoimmune Disease Therapeutics Market
6.6.1 Nigeria Autoimmune Disease Therapeutics Market by Indication
6.6.2 Nigeria Autoimmune Disease Therapeutics Market by Drug Class
6.6.3 Nigeria Autoimmune Disease Therapeutics Market by Distribution Channel
6.7 Rest of LAMEA Autoimmune Disease Therapeutics Market
6.7.1 Rest of LAMEA Autoimmune Disease Therapeutics Market by Indication
6.7.2 Rest of LAMEA Autoimmune Disease Therapeutics Market by Drug Class
6.7.3 Rest of LAMEA Autoimmune Disease Therapeutics Market by Distribution Channel
CHAPTER 7. COMPANY PROFILES
7.1 ABBOTT Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.2 Bio-Rad Laboratories, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expenses
7.3 Johnson and Johnson
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental &Regional Analysis
7.3.4 Research & Development Expenses
7.3.1 Recent strategies and developments:
7.3.1.1 Collaborations, partnerships and agreements:
7.4 GlaxoSmithKline PLC (GSK)
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Acquisition and mergers:
7.4.5.2 Collaborations, partnerships and agreements:
7.4.5.3 Product launches:
7.5 Pfizer, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Collaborations, partnerships and agreements:
7.5.5.2 Approval:
7.6 Merck & Co., Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expenses
7.6.5 Recent strategies and developments:
7.6.5.1 Collaborations, partnerships and agreements:
7.6.5.2 Acquisition and mergers:
7.7 Bayer AG (Bayer Schering Pharma AG)
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Collaborations, partnerships and agreements:
7.8 AbbVie, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expense
7.8.5 Recent strategies and developments:
7.8.5.1 Collaborations, partnerships and agreements:
7.9 Amgen, Inc.
7.9.1 Company overview
7.9.2 Financial Analysis
7.9.3 Regional Analysis
7.9.4 Research & Development Expense
7.9.5 Recent strategies and developments:
7.9.5.1 Product launches:
7.9.5.2 Collaborations, partnerships and agreements:
7.1 Novartis AG
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Research & Development Expense
7.10.5 Recent strategies and developments:
7.10.5.1 Acquisition and mergers:
7.10.5.2 Collaborations, partnerships and agreements:
LIST OF TABLES
TABLE 1 LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2015 - 2018, USD MILLION
TABLE 2 LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2019 - 2025, USD MILLION
TABLE 3 LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 4 LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 5 LAMEA RHEUMATIC DISEASE MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 6 LAMEA RHEUMATIC DISEASE MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 7 LAMEA DIABETES MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 8 LAMEA DIABETES MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 9 LAMEA MULTIPLE SCLEROSIS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 10 LAMEA MULTIPLE SCLEROSIS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 11 LAMEA INFLAMMATORY BOWEL DISEASE MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 12 LAMEA INFLAMMATORY BOWEL DISEASE MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 13 LAMEA OTHER INDICATIONS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 14 LAMEA OTHER INDICATIONS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 15 LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2015 - 2018, USD MILLION
TABLE 16 LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2019 - 2025, USD MILLION
TABLE 17 LAMEA ANTI-INFLAMMATORY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 18 LAMEA ANTI-INFLAMMATORY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 19 LAMEA ANTI-HYPERGLYCEMICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 20 LAMEA ANTI-HYPERGLYCEMICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 21 LAMEA NSAIDS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 22 LAMEA NSAIDS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 23 LAMEA INTERFERONS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 24 LAMEA INTERFERONS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 25 LAMEA OTHER DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 26 LAMEA OTHER DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 27 LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2015 - 2018, USD MILLION
TABLE 28 LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2019 - 2025, USD MILLION
TABLE 29 LAMEA HOSPITAL PHARMACY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 30 LAMEA HOSPITAL PHARMACY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 31 LAMEA ONLINE MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 32 LAMEA ONLINE MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 33 LAMEA RETAIL PHARMACIES AND DRUG STORES MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 34 LAMEA RETAIL PHARMACIES AND DRUG STORES MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 35 LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 36 LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 37 BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2015 - 2018, USD MILLION
TABLE 38 BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2019 - 2025, USD MILLION
TABLE 39 BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 40 BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 41 BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2015 - 2018, USD MILLION
TABLE 42 BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2019 - 2025, USD MILLION
TABLE 43 BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2015 - 2018, USD MILLION
TABLE 44 BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2019 - 2025, USD MILLION
TABLE 45 ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2015 - 2018, USD MILLION
TABLE 46 ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2019 - 2025, USD MILLION
TABLE 47 ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 48 ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 49 ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2015 - 2018, USD MILLION
TABLE 50 ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2019 - 2025, USD MILLION
TABLE 51 ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2015 - 2018, USD MILLION
TABLE 52 ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2019 - 2025, USD MILLION
TABLE 53 UAE AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2015 - 2018, USD MILLION
TABLE 54 UAE AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2019 - 2025, USD MILLION
TABLE 55 UAE AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 56 UAE AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 57 UAE AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2015 - 2018, USD MILLION
TABLE 58 UAE AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2019 - 2025, USD MILLION
TABLE 59 UAE AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2015 - 2018, USD MILLION
TABLE 60 UAE AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2019 - 2025, USD MILLION
TABLE 61 SAUDI ARABIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2015 - 2018, USD MILLION
TABLE 62 SAUDI ARABIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2019 - 2025, USD MILLION
TABLE 63 SAUDI ARABIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 64 SAUDI ARABIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 65 SAUDI ARABIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2015 - 2018, USD MILLION
TABLE 66 SAUDI ARABIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2019 - 2025, USD MILLION
TABLE 67 SAUDI ARABIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2015 - 2018, USD MILLION
TABLE 68 SAUDI ARABIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2019 - 2025, USD MILLION
TABLE 69 SOUTH AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2015 - 2018, USD MILLION
TABLE 70 SOUTH AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2019 - 2025, USD MILLION
TABLE 71 SOUTH AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 72 SOUTH AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 73 SOUTH AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2015 - 2018, USD MILLION
TABLE 74 SOUTH AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2019 - 2025, USD MILLION
TABLE 75 SOUTH AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2015 - 2018, USD MILLION
TABLE 76 SOUTH AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2019 - 2025, USD MILLION
TABLE 77 NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2015 - 2018, USD MILLION
TABLE 78 NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2019 - 2025, USD MILLION
TABLE 79 NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 80 NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 81 NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2015 - 2018, USD MILLION
TABLE 82 NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2019 - 2025, USD MILLION
TABLE 83 NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2015 - 2018, USD MILLION
TABLE 84 NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2019 - 2025, USD MILLION
TABLE 85 REST OF LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2015 - 2018, USD MILLION
TABLE 86 REST OF LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2019 - 2025, USD MILLION
TABLE 87 REST OF LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 88 REST OF LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 89 REST OF LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2015 - 2018, USD MILLION
TABLE 90 REST OF LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2019 - 2025, USD MILLION
TABLE 91 REST OF LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2015 - 2018, USD MILLION
TABLE 92 REST OF LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2019 - 2025, USD MILLION
TABLE 93 KEY INFORMATION – ABBOTT LABORATORIES
TABLE 94 KEY INFORMATION – BIO-RAD LABORATORIES, INC.
TABLE 95 KEY INFORMATION –JOHNSON AND JOHNSON
TABLE 96 KEY INFORMATION – GLAXOSMITHKLINE PLC (GSK)
TABLE 97 KEY INFORMATION – PFIZER, INC.
TABLE 98 KEY INFORMATION – MERCK & CO., INC.
TABLE 99 KEY INFORMATION – BAYER AG
TABLE 100 KEY INFORMATION – ABBVIE, INC.
TABLE 101 KEY INFORMATION – AMGEN, INC.
TABLE 102 KEY INFORMATION – NOVARTIS AG
TABLE 1 LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2015 - 2018, USD MILLION
TABLE 2 LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2019 - 2025, USD MILLION
TABLE 3 LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 4 LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 5 LAMEA RHEUMATIC DISEASE MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 6 LAMEA RHEUMATIC DISEASE MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 7 LAMEA DIABETES MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 8 LAMEA DIABETES MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 9 LAMEA MULTIPLE SCLEROSIS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 10 LAMEA MULTIPLE SCLEROSIS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 11 LAMEA INFLAMMATORY BOWEL DISEASE MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 12 LAMEA INFLAMMATORY BOWEL DISEASE MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 13 LAMEA OTHER INDICATIONS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 14 LAMEA OTHER INDICATIONS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 15 LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2015 - 2018, USD MILLION
TABLE 16 LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2019 - 2025, USD MILLION
TABLE 17 LAMEA ANTI-INFLAMMATORY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 18 LAMEA ANTI-INFLAMMATORY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 19 LAMEA ANTI-HYPERGLYCEMICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 20 LAMEA ANTI-HYPERGLYCEMICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 21 LAMEA NSAIDS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 22 LAMEA NSAIDS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 23 LAMEA INTERFERONS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 24 LAMEA INTERFERONS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 25 LAMEA OTHER DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 26 LAMEA OTHER DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 27 LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2015 - 2018, USD MILLION
TABLE 28 LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2019 - 2025, USD MILLION
TABLE 29 LAMEA HOSPITAL PHARMACY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 30 LAMEA HOSPITAL PHARMACY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 31 LAMEA ONLINE MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 32 LAMEA ONLINE MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 33 LAMEA RETAIL PHARMACIES AND DRUG STORES MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 34 LAMEA RETAIL PHARMACIES AND DRUG STORES MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 35 LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 36 LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 37 BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2015 - 2018, USD MILLION
TABLE 38 BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2019 - 2025, USD MILLION
TABLE 39 BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 40 BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 41 BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2015 - 2018, USD MILLION
TABLE 42 BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2019 - 2025, USD MILLION
TABLE 43 BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2015 - 2018, USD MILLION
TABLE 44 BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2019 - 2025, USD MILLION
TABLE 45 ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2015 - 2018, USD MILLION
TABLE 46 ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2019 - 2025, USD MILLION
TABLE 47 ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 48 ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 49 ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2015 - 2018, USD MILLION
TABLE 50 ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2019 - 2025, USD MILLION
TABLE 51 ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2015 - 2018, USD MILLION
TABLE 52 ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2019 - 2025, USD MILLION
TABLE 53 UAE AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2015 - 2018, USD MILLION
TABLE 54 UAE AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2019 - 2025, USD MILLION
TABLE 55 UAE AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 56 UAE AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 57 UAE AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2015 - 2018, USD MILLION
TABLE 58 UAE AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2019 - 2025, USD MILLION
TABLE 59 UAE AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2015 - 2018, USD MILLION
TABLE 60 UAE AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2019 - 2025, USD MILLION
TABLE 61 SAUDI ARABIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2015 - 2018, USD MILLION
TABLE 62 SAUDI ARABIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2019 - 2025, USD MILLION
TABLE 63 SAUDI ARABIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 64 SAUDI ARABIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 65 SAUDI ARABIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2015 - 2018, USD MILLION
TABLE 66 SAUDI ARABIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2019 - 2025, USD MILLION
TABLE 67 SAUDI ARABIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2015 - 2018, USD MILLION
TABLE 68 SAUDI ARABIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2019 - 2025, USD MILLION
TABLE 69 SOUTH AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2015 - 2018, USD MILLION
TABLE 70 SOUTH AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2019 - 2025, USD MILLION
TABLE 71 SOUTH AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 72 SOUTH AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 73 SOUTH AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2015 - 2018, USD MILLION
TABLE 74 SOUTH AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2019 - 2025, USD MILLION
TABLE 75 SOUTH AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2015 - 2018, USD MILLION
TABLE 76 SOUTH AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2019 - 2025, USD MILLION
TABLE 77 NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2015 - 2018, USD MILLION
TABLE 78 NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2019 - 2025, USD MILLION
TABLE 79 NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 80 NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 81 NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2015 - 2018, USD MILLION
TABLE 82 NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2019 - 2025, USD MILLION
TABLE 83 NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2015 - 2018, USD MILLION
TABLE 84 NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2019 - 2025, USD MILLION
TABLE 85 REST OF LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2015 - 2018, USD MILLION
TABLE 86 REST OF LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2019 - 2025, USD MILLION
TABLE 87 REST OF LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 88 REST OF LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 89 REST OF LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2015 - 2018, USD MILLION
TABLE 90 REST OF LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2019 - 2025, USD MILLION
TABLE 91 REST OF LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2015 - 2018, USD MILLION
TABLE 92 REST OF LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2019 - 2025, USD MILLION
TABLE 93 KEY INFORMATION – ABBOTT LABORATORIES
TABLE 94 KEY INFORMATION – BIO-RAD LABORATORIES, INC.
TABLE 95 KEY INFORMATION –JOHNSON AND JOHNSON
TABLE 96 KEY INFORMATION – GLAXOSMITHKLINE PLC (GSK)
TABLE 97 KEY INFORMATION – PFIZER, INC.
TABLE 98 KEY INFORMATION – MERCK & CO., INC.
TABLE 99 KEY INFORMATION – BAYER AG
TABLE 100 KEY INFORMATION – ABBVIE, INC.
TABLE 101 KEY INFORMATION – AMGEN, INC.
TABLE 102 KEY INFORMATION – NOVARTIS AG
LIST OF FIGURES
FIG 1 METHODOLOGY FOR THE RESEARCH
FIG 1 METHODOLOGY FOR THE RESEARCH
